NTLA Long Put Strategy
NTLA (Intellia Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders.
NTLA (Intellia Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.87B, a beta of 1.82 versus the broader market, a 52-week range of 7.95-28.25, average daily share volume of 6.4M, a public-listing history dating back to 2016, approximately 403 full-time employees. These structural characteristics shape how NTLA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.82 indicates NTLA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long put on NTLA?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current NTLA snapshot
As of June 30, 2026, spot at $16.91, ATM IV 85.00%, IV rank 30.99%, expected move 24.37%. The long put on NTLA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on NTLA specifically: NTLA IV at 85.00% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 24.37% (roughly $4.12 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NTLA expiries trade a higher absolute premium for lower per-day decay. Position sizing on NTLA should anchor to the underlying notional of $16.91 per share and to the trader's directional view on NTLA stock.
NTLA long put setup
The NTLA long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NTLA near $16.91, the first option leg uses a $17.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NTLA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NTLA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $17.00 | $1.30 |
NTLA long put risk and reward
- Net Premium / Debit
- -$130.00
- Max Profit (per contract)
- $1,569.00
- Max Loss (per contract)
- -$130.00
- Breakeven(s)
- $15.70
- Risk / Reward Ratio
- 12.069
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
NTLA long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on NTLA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | +$1,569.00 |
| $3.75 | -77.8% | +$1,195.22 |
| $7.49 | -55.7% | +$821.44 |
| $11.22 | -33.6% | +$447.66 |
| $14.96 | -11.5% | +$73.88 |
| $18.70 | +10.6% | -$130.00 |
| $22.44 | +32.7% | -$130.00 |
| $26.17 | +54.8% | -$130.00 |
| $29.91 | +76.9% | -$130.00 |
| $33.65 | +99.0% | -$130.00 |
When traders use long put on NTLA
Long puts on NTLA hedge an existing long NTLA stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying NTLA exposure being hedged.
NTLA thesis for this long put
The market-implied 1-standard-deviation range for NTLA extends from approximately $12.79 on the downside to $21.03 on the upside. A NTLA long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long NTLA position with one put per 100 shares held. Current NTLA IV rank near 30.99% is mid-range against its 1-year distribution, so the IV signal is neutral; the long put thesis on NTLA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NTLA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NTLA-specific events.
NTLA long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NTLA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NTLA alongside the broader basket even when NTLA-specific fundamentals are unchanged. Long-premium structures like a long put on NTLA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NTLA chain quotes before placing a trade.
Frequently asked questions
- What is a long put on NTLA?
- A long put on NTLA is the long put strategy applied to NTLA (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With NTLA stock trading near $16.91, the strikes shown on this page are snapped to the nearest listed NTLA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NTLA long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the NTLA long put priced from the end-of-day chain at a 30-day expiry (ATM IV 85.00%), the computed maximum profit is $1,569.00 per contract and the computed maximum loss is -$130.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NTLA long put?
- The breakeven for the NTLA long put priced on this page is roughly $15.70 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NTLA market-implied 1-standard-deviation expected move is approximately 24.37%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on NTLA?
- Long puts on NTLA hedge an existing long NTLA stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying NTLA exposure being hedged.
- How does current NTLA implied volatility affect this long put?
- NTLA ATM IV is at 85.00% with IV rank near 30.99%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.